{
    "Trade/Device Name(s)": [
        "Access BR Monitor",
        "Access BR Monitor Reagents",
        "Access BR Monitor Calibrators"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K240403",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072612",
        "K033036"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOI"
    ],
    "Summary Letter Date": "May 9, 2024",
    "Summary Letter Received Date": "February 9, 2024",
    "Submission Date": "April 29, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "CA 15-3 antigen"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems",
        "Access 2 Immunoassay System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle",
        "Two-site immunoenzymatic (sandwich) assay",
        "Automated"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Access BR Monitor assay using chemiluminescent immunoassay to quantitatively determine CA 15-3 antigen in human serum and plasma on DxI 9000 Access Immunoassay Analyzer",
    "Indications for Use Summary": "Quantitative measurement of CA 15-3 antigen in human serum and plasma (heparin) to aid in management of breast cancer patients; serial testing should be used with other clinical methods for monitoring breast cancer",
    "fda_folder": "Immunology"
}